Linked CD4+/CD8+ T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression https://www.biorxiv.org/content/10.1101/2023.05.06.539290v1?med=mas
Linked CD4+/CD8+ T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression https://www.biorxiv.org/content/10.1101/2023.05.06.539290v1?med=mas
@biorxivpreprint The here proposed relevant link between an neoepitope-dependent equal recognition by CD4+ and CD8+ T cells and positive response to #immunotherapy should be easily tested for confirmation in clinical samples from #vaccination trials, e.g. in #melanoma or #headneckcancers patients...but why have those one-vaccine-for-all-patients trials not shown positive results: no CD4+/CD8+ induction? Or no good neoepitope? Both? Else? @cyrilpedia @CastlTrAstonDrs @rio_sugimura